文献速递免疫规划传染病防控与疫情报告

波兰引入10价肺炎球菌结合疫苗前肺炎球菌脑膜炎的流行病学特征

Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland.
PubMed 文献 · Vaccine · 2019-01-09

基于波兰2005-2015年全国监测数据,肺炎球菌脑膜炎报告发病率从0.21/10万升至0.47/10万,年均增长7%;50岁以上人群增幅显著,<5岁儿童中PCV10和PCV13血清型分别占75%和80%;28%分离株对青霉素耐药,13%对头孢噻肟不敏感。

要点

  • 2005-2015年波兰肺炎球菌脑膜炎报告发病率年均增长7%,从0.21升至0.47/10万。
  • <5岁儿童中PCV10和PCV13血清型分别占75%和80%,为疫苗引入提供基线。
  • 28%分离株对青霉素耐药,13%对头孢噻肟不敏感;PCV10血清型占比从52%降至41%。

核心结论

  • 波兰引入PCV10前肺炎球菌脑膜炎报告发病率呈上升趋势,以50岁以上人群增幅为主。
  • PCV10血清型在儿童中占比较高且近年比例下降,疫苗引入可能显著影响疾病负担。

研究设计与样本

  • 基于2005-2015年波兰国家法定监测系统实验室确诊病例, linked 脑脊液分离株数据至国家细菌性脑膜炎参考中心。
  • 采用负二项回归(Newey-West法)检验发病率趋势,卡方检验比较2008-2011与2012-2015血清型分布变化。

主要发现

  • 2005-2015年肺炎球菌脑膜炎总体报告发病率从0.21升至0.47/10万,年均增长7%(率比1.07;95%CI 1.06-1.08)。
  • 15-49岁、50-64岁、65-74岁和≥75岁人群年增长率分别为3%(1.02-1.05)、12%(1.10-1.13)、18%(1.16-1.19)和9%(1.07-1.10)。
  • <5岁儿童中PCV10和PCV13血清型分别占75%和80%;PCV10血清型所致病例比例从2008-2011的52%降至2012-2015的41%(p<0.01)。
  • 28%分离株对青霉素耐药,13%对头孢噻肟不敏感。

关键数值与推荐

  • 肺炎球菌脑膜炎报告发病率年均增长7%(率比1.07;95%CI 1.06-1.08)。
  • PCV10血清型比例从52%降至41%(p<0.01)。
  • 青霉素耐药占28%,头孢噻肟不敏感占13%。

临床怎么用

  • 为评估PCV10引入后肺炎球菌脑膜炎负担变化提供基线数据,尤其关注疫苗血清型覆盖和抗菌药物耐药。
  • 监测数据显示50岁以上人群发病率增长显著,应加强该人群的疾病负担评估与防控。

局限性

  • 基于监测系统报告数据,可能存在漏报或报告不全。
  • 为PCV10引入前的基线分析,无法直接评估疫苗效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poland introduced the 10-valent conjugate pneumococcal vaccine (PCV10) into the childhood immunization program in January 2017. During previous decades, considerable changes had occurred in the surveillance system for invasive pneumococcal disease. Therefore, to provide baseline data on pneumococcal diseases before PCV10 introduction, we evaluated the epidemiology of pneumococcal meningitis (PM), the only syndrome monitored consistently since 1970. METHODS: Based on laboratory-confirmed cases reported during 2005-2015, we calculated the reported rates, serotypes distribution and antimicrobial resistance of pneumococcal meningitis isolates. Data from the mandatory national surveillance system was linked with data on cerebrospinal fluid isolates submitted to the National Reference Centre for Bacterial Meningitis. We used negative binomial regression with Newey West method to test for trend in rates of pneumococcal meningitis notified during 2005-2015 and Chi-squared test to assess changes in the serotype distribution from 2008-2011 to 2012-2015. RESULTS: From 2005 to 2015, the overall reported incidence of PM increased from 0.21 to 0.47 cases per 100,000 population, average yearly increase of 7% (rate ratio 1.07; 95% CI 1.06-1.08). The increase was primarily due to annual increase of 3% (1.02-1.05) among 15-49 years of age, 12% (95% CI: 1.10-1.13) among 50-64 years of age, 18% (95% CI: 1.16-1.19) among persons 65-74 years of age and 9% (95% CI 1.07-1.10) among persons ≥75 years of age. In children <5 years of age, serotypes included in PCV10 and PCV13 accounted for 75% and 80% of reported isolates, respectively. From 2008-2011 to 2012-2015, the proportion of PM cases caused by PCV10 serotypes decreased from 52% to 41% (p < 0.01). Overall, 28% of isolates were resistant to penicillin and 13% were non-susceptible to cefotaxime. CONCLUSIONS: The introduction of PCV10 into national immunization program may have considerable impact on disease burden, especially on number of cases caused by isolates non-susceptible to antimicrobials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Polkowska A, Skoczyńska A, Paradowska-Stankiewicz I, et al. Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland. Vaccine. 2019. PMID: 30638798. doi:10.1016/j.vaccine.2018.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。